Doctors have not had a new treatment for gram-negative bacteria in the last 50...
Doctors have not had a new treatment for gram-negative bacteria in the last 50 years, and no potential drugs have entered clinical trials since 2010. The research could pave the way for much needed new treatments for antibiotic resistant superbugs

Source: University of Sheffield

MRSA, E.Coli & co

New compound kills antibiotic resistant superbugs

Researchers at the University of Sheffield have developed a new compound that is able to kill both gram-positive and gram-negative antibiotic-resistant bacteria.

Gram-positive and gram-negative bacteria have different cell wall structures, but the new antibiotic compound is able to pass through the cell wall of both forms of bacteria and then bind to the DNA. The findings pave the way for developing new treatments for all kinds of antibiotic resistant bacteria, including the gram-positive MRSA and gram-negative E.Coli.

The team from the University of Sheffield has previously developed new compound leads that specifically target gram-negative bacteria, but this new compound is a broad spectrum antimicrobial which means it is just as effective in both types of bacteria.

Gram-negative bacteria strains are particularly difficult to treat as their cell wall prevents drugs from getting into the microbe, they can cause infections including pneumonia, urinary tract infections and bloodstream infections.

Professor Jim Thomas, Principal Investigator of the research from the University of Sheffield, said: "Antimicrobial resistance is an increasing problem with many studies predicting a medical global emergency, so broad spectrum antimicrobials which work against resistant pathogens are urgently needed. As the compound is luminescent it glows when exposed to light. This means we were able to follow the uptake and effect on bacteria using advanced microscopy techniques available at STFC's Rutherford Appleton Lab."

Antimicrobial resistance is already responsible for 25,000 deaths in the EU each year, and unless this rapidly emerging threat is addressed, it's estimated by 2050 more than 10 million people could die every year due to antibiotic resistant infections. Doctors have not had a new treatment for gram-negative bacteria in the last 50 years, and no potential drugs have entered clinical trials since 2010.

Source: University of Sheffield

08.09.2020

Read all latest stories

Related articles

Photo

Before clinical use of antibiotics

Superbug MRSA arose in hedgehogs

A type of the antibiotic resistant superbug MRSA arose in nature long before the use of antibiotics in humans and livestock, which has traditionally been blamed for its emergence.

Photo

Pathogenic microbes

Cigarette smoke makes MRSA superbug bacterium more drug-resistant

Cigarette smoke can make MRSA bacterial strains more resistant to antibiotics, new research from the University of Bath has shown. In addition cigarette smoke exposure can make some strains of…

Photo

Combined with antibiotics

Bacteria-killing viruses to fight antibiotic-resistant bacteria

Researchers have found a way to defeat the multi-resistant bacterium Mycobacterium abscessus, a relative of the causes of tuberculosis and leprosy.

Related products

Associates of Cape Cod – Fungitell STAT Assay

Identification/Susceptibility

Associates of Cape Cod – Fungitell STAT Assay

Associates of Cape Cod Europe GmbH
DRG Instruments – DRG:Hybrid-XL

Immunochemistry

DRG Instruments – DRG:Hybrid-XL

DRG Instruments GmbH
Hologic – Novodiag System

Automation & sample processing

Hologic – Novodiag System

Hologic, Inc.
MolGen – PurePrep 96

Extraction

MolGen – PurePrep 96

MolGen
Siemens Healthineers – Versant HCV Genotype 2.0 Assay (LiPA)

Infectious Disease/Hepatitis

Siemens Healthineers – Versant HCV Genotype 2.0 Assay (LiPA)

Siemens Healthineers
Subscribe to Newsletter